CLAIMS

What is claimed is:

1. Use of a plurality of pharmaceutical compositions in the preparation of a medicament for use in combinatorial therapy to treat a tumor, characterized in that:
   at least a first pharmaceutical composition reverts an escape phase of the tumor, the first pharmaceutical composition comprising a drug selected from the group consisting of bendamustine, bortezomib, cabazitaxel, chlorambucil, cisplatin, cyclophosphamide, dasatinib, docetaxel, doxorubicin, epirubicin, erlotinib, etoposide, everolimus, 5-fluorouracil, gefitinib, gemcitabine, idarubicin, hydroxyurea, imatinib, lapatinib, melphalan, mitoxantrone, nilotinib, oxiplatin, paclitaxel, pazopanib, pemetrexed, rapamycin, romidepsin, sorafenib, sunitinib, teniposide, temozolomide, trabectedin, vemurafenib, vinblastine, vinorelbine, and vincristine;
   at least a second pharmaceutical composition induces an elimination phase of the tumor, the second pharmaceutical composition is selected from the group consisting of a recombinant bacterial vaccine, a recombinant viral vaccine, a recombinant yeast vaccine, a natural killer (NK) cell, IL-2, IL-7, IL-15, IL-17, IL-21, an IL-15 superagonist, and a combination thereof; and
   at least a third pharmaceutical composition maintains an equilibrium phase of the tumor, the third pharmaceutical composition comprising a checkpoint inhibitor.

2. The use of claim 1 wherein the drug of the first pharmaceutical composition is bound to an albumin, wherein the albumin is optionally a nanoparticulate albumin.

3. The use of claim 2 further comprising an antibody or fragment thereof bound to the albumin.

4. The use of claim 2 or claim 3 wherein the drug is paclitaxel.

5. The use of any one of claims 2-4 wherein the antibody or fragment thereof is selected form the group consisting of Reopro , Kadcyla, Campath, Simulect, Avastin, Benlysta, Adcetris, Cimzia, Rbitux, Prolia, Zevalin, Tysabri, Gazyva, Arzerra, Xolair, Vectibix, Perjeta, Cyramza, Lucentis, Rituxan, Bexar, Yondelis, and Herceptin.

6. The use of any one of claims 3-5 wherein the antibody or fragment thereof binds specifically to a component of a necrotic cell, the component comprising a nucleolin, histone protein, or DNA.

7. The use of claim 1 wherein the first pharmaceutical composition further comprises a drug that inhibits at least one of a T-reg cell, a myeloid derived suppressor cell, and a M2 macrophage.

8. The use of claim 7 wherein the drug is RP-182.

9. The use of any one of claims 1-8 wherein the second pharmaceutical composition is selected from the group consisting of a recombinant bacterial vaccine, a recombinant viral vaccine, or a recombinant yeast vaccine.

10. The use of claim 9 wherein the recombinant bacterial vaccine, the recombinant viral vaccine, or the recombinant yeast vaccine is genetically engineered to express at least one of a tumor associated antigen and a patient and tumor specific neoepitope.

11. The use of claim 10 wherein the tumor associated antigen is selected from the group consisting of MUC1, CEA, HER2, Brachyury, and an oncogenic Ras mutant protein.

12. The use of any one of claims 1-8 wherein the second pharmaceutical composition comprises a natural killer cell.

13. The use of claim 12 wherein the natural killer cell is an aNK cell, a haNK cell, or a taNK cell.

14. The use of any one of claims 1-8 wherein the second pharmaceutical composition is selected from the group consisting of IL-2, IL-7, IL-15, IL-17, IL-21, and an IL-15 superagonist.

15. The use of claim 14 wherein the second pharmaceutical composition comprises IL-15 superagonist.

16. The use of any one of claims 1-15 wherein the third pharmaceutical composition comprises avelumab.

17. The use of any one of claims 1-15 wherein the checkpoint inhibitor is a PD-1 inhibitor or a CTLA4 inhibitor.

18. The use of any one of claims 1-17 wherein low dose radiation is to be further administered to the tumor.